Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1779964 | 0.78 | NOTUM (0.40) | NOTUMKMT2AFFAR1SLC6A4SLC6A3 | |
| SCHEMBL1780380 | 0.73 | CCR2 (0.48) | NOTUMKDRL3MBTL1LMNAGAA | |
| SCHEMBL24477898 | 0.66 | GAA (0.61) | NOTUMKDRL3MBTL1LMNAGAA | |
| SCHEMBL30483542 | 0.66 | GAA (0.61) | NOTUMKDRL3MBTL1LMNAGAA | |
| SCHEMBL197395 | 0.66 | NOTUM (0.62) | NOTUMKDRL3MBTL1LMNAGAA | |
| SCHEMBL9120515 | 0.65 | NPSR1 (0.62) | NOTUML3MBTL1LMNAGAA | |
| SCHEMBL8136081 | 0.65 | NOTUM (0.42) | NOTUMKDRL3MBTL1LMNAMAPT | |
| SCHEMBL8158392 | 0.65 | NOTUM (0.42) | NOTUMKDRL3MBTL1LMNAGAA | |
| SCHEMBL8997531 | 0.65 | L3MBTL1 (0.48) | NOTUML3MBTL1LMNAGAAKMT2A | |
| SCHEMBL29079190 | 0.63 | GAA (0.56) | NOTUMKDRL3MBTL1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507559-B2 | Cyclohexenyl modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2318352-B1 | CYCLOHEXENYL COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20110118354-A1 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118354-A1 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | NOTUM 2861/4885KDR 1295/4885L3MBTL1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.